Cargando…

Comment on “Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis”

Detalles Bibliográficos
Autores principales:	Bellan, Mattia, Avanzi, Gian Carlo, Pirisi, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728867/ https://www.ncbi.nlm.nih.gov/pubmed/31501794 http://dx.doi.org/10.5114/ceh.2019.85075

Ejemplares similares

Increased serum interleukin-6 levels in patients with hidradenitis suppurativa
por: Xu, Haoxiang, et al.
Publicado: (2017)

Commenting on “Prognostic and diagnostic significance of copeptin in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from ACE 2 study” by Jacob A. Winther and colleagues
por: Castello, Luigi Mario, et al.
Publicado: (2018)

Comment on “Excessive Sodium Bicarbonate Infusion May Result in Osmotic Demyelination Syndrome During Treatment of Diabetic Ketoacidosis: A Case Report” by Hsieh et al.
por: Castello, Luigi Mario, et al.
Publicado: (2019)

Kinetics of serum hepcidin and interleukin-6 levels following COVID-19 infection in hemodialysis patients
por: Touzot, Maxime, et al.
Publicado: (2021)

Serum Levels of Interleukin-6 and Interleukin-10 as Biomarkers for Hepatocellular Carcinoma in Egyptian Patients
por: Othman, Mohamed S., et al.
Publicado: (2013)

Comment on “Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma”
por: Qian, Xinye
Publicado: (2023)

Comment on “Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6”
por: Cattaneo, Dario, et al.
Publicado: (2021)

Serum exosomal long noncoding RNA CRNDE level for hepatocellular carcinoma diagnosis
por: Huang, Xiao‐Li, et al.
Publicado: (2021)

Comment on “Metabolic Changes and Serum Ghrelin Level in Patients with Psoriasis”
por: Agilli, Mehmet, et al.
Publicado: (2015)

A comment on ‘A morpho-molecular prognostic model for hepatocellular carcinoma'
por: Halil Sahin, I, et al.
Publicado: (2013)

Comment on “Outcomes of curative liver resection for hepatocellular carcinoma in patients with cirrhosis”
por: Tang, Xiao-Long, et al.
Publicado: (2022)

Response to: “Comment on Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma”
por: Famularo, Simone, et al.
Publicado: (2023)

Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis
por: Shakiba, Ebrahim, et al.
Publicado: (2018)

Comment on ‘Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma'
por: Guthrie, G, et al.
Publicado: (2013)

Comment on “Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis”
por: Mo, Han-Yue, et al.
Publicado: (2016)

Relevance of Serum Levels of Interleukin-6 and Syndecan-1 in Patients with Hepatocellular Carcinoma
por: Metwaly, Heba A., et al.
Publicado: (2012)

The Gas6/TAM System and Multiple Sclerosis
por: Bellan, Mattia, et al.
Publicado: (2016)

Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?’
por: Kow, Chia Siang, et al.
Publicado: (2023)

Serum vascular endothelial growth factor load and interleukin-6 in cancer patients
por: O'Byrne, K J, et al.
Publicado: (2000)

Response to: Comment on “Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis”
por: Yuan, Peng, et al.
Publicado: (2016)

Comment on: “Stereotactic body radiation therapy versus radiofrequency ablation in patients with small hepatocellular carcinoma: a systematic review and meta-analysis”
por: Liu, Xiangyu, et al.
Publicado: (2022)

Comment on ‘Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area'
por: Grizzi, F, et al.
Publicado: (2016)

Comment on ‘Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion’
por: Huo, Teh-Ia, et al.
Publicado: (2017)

Serum Levels of Interleukin 10 (IL-10) in Patients with Type 2 Diabetes
por: Yaghini, N, et al.
Publicado: (2011)

Authors’ Reply to Cattaneo et al.: “Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6”
por: Cojutti, Pier Giorgio, et al.
Publicado: (2021)

Serum vascular endothelial growth factor load and interleukin-6 in cancer patients – reply
por: Salgado, R, et al.
Publicado: (2000)

Reply to: Comment on ‘Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area'
por: Sideras, Kostandinos, et al.
Publicado: (2016)

Reply to ‘Comment on ‘Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion’ ’
por: Waked, Iman, et al.
Publicado: (2017)

Sorafenib with or without concurrent transarterial chemoembolization in hepatocellular carcinoma: a cautionary comment of STAH trial
por: Chen, Jia-Hao, et al.
Publicado: (2020)

Re: Serum tissue factor as biomarker for renal clear cell carcinoma: a comment
por: Joob, Beuy, et al.
Publicado: (2018)

Comment on: ‘Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade'
por: Cucchetti, Alessandro, et al.
Publicado: (2016)

Skin Sclerosis with Elevation of Serum Interleukin-6 That Is Possibly Associated with Immunoglobulin 4-Related Disease
por: Motegi, Sei-ichiro, et al.
Publicado: (2014)

Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19
por: Gade, Akhil R., et al.
Publicado: (2020)

Interleukin-6 level, right ventricular systolic dysfunction, and coronavirus disease 2019
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Reply to: “Reconsidering low HDL-cholesterol levels as a predictive factor for the development of hepatocellular carcinoma”
por: Crudele, Lucilla, et al.
Publicado: (2023)

COVID-19 Biomarkers at the Crossroad between Patient Stratification and Targeted Therapy: The Role of Validated and Proposed Parameters
por: Rizzi, Manuela, et al.
Publicado: (2023)

Growth Arrest-Specific Gene 6 Administration Ameliorates Sepsis-Induced Organ Damage in Mice and Reduces ROS Formation In Vitro
por: Salmi, Livia, et al.
Publicado: (2021)

Comment on “A Sustained Reduction in Serum Cholinesterase Enzyme Activity Predicts Patient Outcome following Sepsis”
por: Chiarla, Carlo, et al.
Publicado: (2019)

Reply to: Comment on: ‘Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade'
por: Johnson, Philip, et al.
Publicado: (2016)

Gas6/TAM Signaling Components as Novel Biomarkers of Liver Fibrosis
por: Smirne, Carlo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_97g1i0q9cg4en6iq9co3g36083